Literature DB >> 24081504

Dual immunostaining of cervical cytology specimens with atypical squamous cells for p16/Ki-67 does not exclude the existence of a high-grade squamous intraepithelial lesion.

Yu-Jin Koo1, Ho-Suap Hahn, In-Ho Lee, Kyung-Taek Lim, Ki-Heon Lee, Hye-Sun Kim, Tae-Jin Kim, Yi-Kyeong Chun, Hy-Sook Kim, Sung-Ran Hong.   

Abstract

This study was conducted to evaluate the accuracy of p16/Ki-67 dual immunostaining compared to high-risk human papillomavirus (HR-HPV) DNA testing for cervical intraepithelial neoplasia (CIN) in women with atypical squamous cells, cytology not excluding high-grade squamous intraepithelial lesion (ASC-H). Data were collected from 73 patients diagnosed to have ASC-H on a Pap smear who were HPV genotyped and had histological examination of a cervical biopsy. The CINtecPLUS kit was used on residual liquid-based material, and the immunoreactivity of dual-stained cells was graded according to the number as follows: G1 (1-5 positive cells), G2 (6-10), G3 (11-20), and G4 (> 20). Accuracy was evaluated based on the histological examination of colposcopy-guided biopsy or cervical conization on follow-up. Of the 70 patients with available data, positive p16/Ki-67 was associated with histological severity as follows: 15% in negative histology, 67% in CIN 1, 90% in CIN 2, and 100% in CIN 3. The average grade of positive p16/Ki-67 staining also increased from 0.2 in histologically negative cases to 1.2 in CIN 1, 2.4 in CIN 2, and 2.9 in CIN 3 (p < 0.01). For patients with CIN 2 or higher, p16/Ki-67 had a sensitivity of 94.6% and a specificity of 75.8%, while HR-HPV testing showed a sensitivity of 67.6% and a specificity of 66.7%. p16/Ki-67 immunostaining demonstrated better accuracy than HR-HPV for detecting CIN 2 or higher in patients with ASC-H cytology. Given the higher concordance with histological diagnosis, the grading system of positive p16/Ki-67 can be a useful adjunct for predicting high-grade lesions in clinical practice.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24081504     DOI: 10.1007/s00428-013-1483-4

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  22 in total

1.  The accuracy of colposcopic biopsy: analyses from the placebo arm of the Gardasil clinical trials.

Authors:  Mark H Stoler; Michelle D Vichnin; Alex Ferenczy; Daron G Ferris; Gonzalo Perez; Jorma Paavonen; Elmar A Joura; Henning Djursing; Kristján Sigurdsson; Lucy Jefferson; Frances Alvarez; Heather L Sings; Shuang Lu; Margaret K James; Alfred Saah; Richard M Haupt
Journal:  Int J Cancer       Date:  2011-03-15       Impact factor: 7.396

2.  Assessment of cervical intraepithelial neoplasia (CIN) with colposcopic biopsy and efficacy of loop electrosurgical excision procedure (LEEP).

Authors:  Nina Duesing; Joerg Schwarz; Matthias Choschzick; Fritz Jaenicke; Friederike Gieseking; Rana Issa; Sven Mahner; Linn Woelber
Journal:  Arch Gynecol Obstet       Date:  2012-08-03       Impact factor: 2.344

3.  Overexpression of p16(INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri.

Authors:  R Klaes; T Friedrich; D Spitkovsky; R Ridder; W Rudy; U Petry; G Dallenbach-Hellweg; D Schmidt; M von Knebel Doeberitz
Journal:  Int J Cancer       Date:  2001-04-15       Impact factor: 7.396

4.  Bethesda 2001 implementation and reporting rates: 2003 practices of participants in the College of American Pathologists Interlaboratory Comparison Program in Cervicovaginal Cytology.

Authors:  Diane D Davey; Margaret H Neal; David C Wilbur; Terence J Colgan; Patricia E Styer; Dina R Mody
Journal:  Arch Pathol Lab Med       Date:  2004-11       Impact factor: 5.534

5.  Impact of HPV testing, HPV vaccine development, and changing screening frequency on national Pap test volume: projections from the National Health Interview Survey (NHIS).

Authors:  Isam A Eltoum; Janie Roberson
Journal:  Cancer       Date:  2007-02-25       Impact factor: 6.860

6.  Practices of participants in the college of american pathologists interlaboratory comparison program in cervicovaginal cytology, 2006.

Authors:  Galen M Eversole; Ann T Moriarty; Mary R Schwartz; Amy C Clayton; Rhona Souers; Lisa A Fatheree; Beth A Chmara; William D Tench; Michael R Henry; David C Wilbur
Journal:  Arch Pathol Lab Med       Date:  2010-03       Impact factor: 5.534

7.  Evaluation of cervical cone biopsies for coexpression of p16INK4a and Ki-67 in epithelial cells.

Authors:  Miriam Reuschenbach; Mirjam Seiz; Christina von Knebel Doeberitz; Svetlana Vinokurova; Alexander Duwe; Ruediger Ridder; Heike Sartor; Friedrich Kommoss; Dietmar Schmidt; Magnus von Knebel Doeberitz
Journal:  Int J Cancer       Date:  2011-06-10       Impact factor: 7.396

8.  Performance of p16/Ki-67 immunostaining to detect cervical cancer precursors in a colposcopy referral population.

Authors:  Nicolas Wentzensen; Lauren Schwartz; Rosemary E Zuna; Katie Smith; Cara Mathews; Michael A Gold; R Andy Allen; Roy Zhang; S Terence Dunn; Joan L Walker; Mark Schiffman
Journal:  Clin Cancer Res       Date:  2012-06-06       Impact factor: 12.531

9.  Evaluation of p16(INK4a)/Ki-67 dual stain in comparison with an mRNA human papillomavirus test on liquid-based cytology samples with low-grade squamous intraepithelial lesion.

Authors:  Marianne Waldstrøm; Rikke Kølby Christensen; Dorthe Ørnskov
Journal:  Cancer Cytopathol       Date:  2012-09-17       Impact factor: 5.284

10.  Minichromosome maintenance 7 protein is a reliable biological marker for human cervical progressive disease.

Authors:  Soraya Lobato; Alexandre Tafuri; Paula Ávila Fernandes; Marcelo Vidigal Caliari; Marcos Xavier Silva; Marcelo Antônio Pascoal Xavier; Annamaria Ravara Vago
Journal:  J Gynecol Oncol       Date:  2012-01-09       Impact factor: 4.401

View more
  4 in total

Review 1.  [Indications for p16/Ki-67 in cervical cytology].

Authors:  P Ziemke; H Griesser
Journal:  Pathologe       Date:  2017-02       Impact factor: 1.011

Review 2.  Triage of ASC-H: A meta-analysis of the accuracy of high-risk HPV testing and other markers to detect cervical precancer.

Authors:  Lan Xu; Freija Verdoodt; Nicolas Wentzensen; Christine Bergeron; Marc Arbyn
Journal:  Cancer Cytopathol       Date:  2015-11-30       Impact factor: 5.284

3.  Immunocytochemical study of TOP2A and Ki-67 in cervical smears from women under routine gynecological care.

Authors:  Adrya Lúcia Peres; Keilla Maria Paz E Silva; Rosângela Ferreira Frade de Araújo; José Luiz de Lima Filho; Mário Ribeiro de Melo Júnior; Danyelly Bruneska Gondim Martins; Nicodemos Teles de Pontes Filho
Journal:  J Biomed Sci       Date:  2016-05-12       Impact factor: 8.410

Review 4.  The Role of p16/Ki-67 Immunostaining, hTERC Amplification and Fibronectin in Predicting Cervical Cancer Progression: A Systematic Review.

Authors:  Septimiu Toader Voidăzan; Caterina Dianzani; Mădălina Aurelia Husariu; Bíborka Geréd; Sabin Gligore Turdean; Cosmina Cristina Uzun; Zsolt Kovacs; Florin Francisc Rozsnyai; Nicoleta Neagu
Journal:  Biology (Basel)       Date:  2022-06-23
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.